Material Educativo del Baylor College : Manejo de las Dislipidemias.

Estimados  colegas, voy  dejarles  esta página a vuestra  consideración :  Sobre   uno  de las  patologías ( trastornos metabólicos) más  frecuentes en medicina, (  DISLIPIDEMIAS) .
Conviene hacer  marcos  de referencia  gnoseológicos,   para  facilitar  su estudio:


1.   Riesgo cardio metabólico.
2.  Manejo  de las  dislipidemias   evolución de los  conceptos.
3.  Guías  para la  valoración del  riesgo  y manejo.
4.  Dislipidemia , inflamación  y ateroesclerosis.
5. Dislipidemia, Diabetes  y  ECV.
6. HDL , Enfermedad  Coronaria

                                        Desde  el  Baylor  College  Lipids  On  Line:

Dejo  a Uds  las  Series  del  Baylor  College:

Clinical Cases

A Case of a Patient with Diabetic Dyslipidemia

MADHURI VASUDEVAN, MD

A Patient With Coronary Artery Disease and Low High-Density Lipoprotein

TARA DALL, MD

A Case of Metabolic Syndrome and Elevated High-Sensitivity C-Reactive Protein: Approach to Management

MADHURI M. VASUDEVAN, MD, MPH

Consideration of Polypharmacology in Relation to Effective Weight Reduction: A Patient on Antipsychotic Medication

VIJAY NAMBI, MD AND MADHURI M.VASUDEVAN, MD, MPH

Consideration of Polypharmacology in Regards to Effective Weight Reduction: A Patient on Diabetes Medication

PETER H. JONES, MD

A Mexican American Woman with Multiple Metabolic Risk Factors

STEPHEN HAFFNER, MD

Benefits of Moderate Weight Loss in Reducing Cardiometabolic Risk

PETER H. JONES, MD

The Patient with Severe Hypertriglyceridemia

CHRISTIE M. BALLANTYNE, MD

Management of the Patient with Familial Hypercholesterolemia

PETER H. JONES, MD

The Patient with a Statin Intolerance

PETER H. JONES, MD

Lipid Treatment and Goal Attainment: A Hispanic Male with CHD and Diabetes

PETER H. JONES, MD

Cardiometabolic Risk

Increased Cardiovascular Disease Risk in Type 2 Diabetes: Pathophysiology

WILLA A. HSUEH, MD

View as a CME activity

Relationship of Glycemia to Cardiovascular Disease: Role of Antidiabetic Agents in Cardiovascular Risk Reduction

RICHARD W. NESTO, MD

Prevention of Diabetes

STEVEN HAFFNER, MD

Therapeutic Options for Modifying Cardiovascular and Metabolic Risk Factors

LOUIS J. ARONNE, MD

Effects of Physical Activity and Exercise on Reducing Risk for Cardiovascular Disease and Diabetes, with a Focus on the Obese Patient

TIM CHURCH, MD, MPH, PHD

The Metabolic Syndrome: Introduction and Definitions

STEVEN M. HAFFNER, MD

Strategies for Lifestyle Modification in the Prevention of Diabetes and Cardiovascular Disease

ANTHONY N. FABRICATORE, PHD, AND THOMAS A. WADDEN, PHD

C-Reactive Protein: A Marker of Risk

PETER W. F. WILSON, MD

Epidemiology of Insulin Resistance, Diabetes Mellitus and CHD

STEVEN M. HAFFNER, MD

Evolving Concepts in Lipid Management

Role of Omega-3 Fatty Acids in Cardiovascular Disease Prevention

WILLIAM S. HARRIS, PHD

C-Reactive Protein: A Target of Therapy

CHRISTOPHER P. CANNON, MD

Combination Lipid-Altering Drug Therapy with Statins: An Update

HAROLD BAYS, MD

Cholesterol Metabolism and the Concept of Dual Inhibition

DAVID E. COHEN, MD, PHD

Guidelines for Risk Assessment and Management

Initiating and Monitoring Statin Therapy

KIMBERLY K. BIRTCHER, MS, PHARMD, BCPS, CDE, CLS

View as a CME Activity

AHA/ACC Secondary Prevention Guidelines and the Evidence to Support Them

GREGG C. FONAROW, MD

Lifestyle Interventions: Dietary Therapy, Physical Activity, Weight Control

NEIL J. STONE, MD

Selecting Successful Lipid-Lowering Treatments

JAMES M. MCKENNEY, PHARMD

ATP III: New Approaches in Identifying and Treating High-Risk Patients

STEVEN M. HAFFNER, MD

New Evidence and the Guidelines: Is a Revision Needed?

Heart Protection Study

RORY COLLINS, MB BS

Dyslipidemia, Inflammation and Atherosclerosis

Sitosterolemia: A Rare Genetic Disorder Leads to Insight into an Important Physiological Process

SHAILESH B. PATEL, BM, CHB, FRCP

Inflammatory Markers, Pharmacotherapy and Clinical Trials

PAUL RIDKER, MD
CHRISTIE M. BALLANTYNE, MD

Inflammation and Pathogenesis of Atherothrombotic Disease

PETER LIBBY, MD

Role of Lipoproteins in Inflammation

PHILIP J. BARTER, MD, PHD

Epidemiology of Inflammatory Markers and CHD: Evidence for High-Sensitivity C-Reactive Protein

PAUL RIDKER, MD

Dyslipidemia, Diabetes and CHD

Diabetic Dyslipidemia and Atherosclerosis

HENRY GINSBERG, MD

Clinical Trials and Guidelines for Lipid Management in the Diabetic Patient

STEVEN M. HAFFNER, MD

Clinical Evaluation and Nonlipid Treatment of CAD in the Diabetic Patient

RICHARD NESTO, MD

HDL and Coronary Heart Disease

High-Density Lipoprotein and the Epidemiology of Coronary Heart Disease

MICHAEL MILLER, MD, FACC, FAHA

View as a CME Activity

Coronary Imaging and Coronary Event Trials

B. GREG BROWN, MD

Current and Emerging Pharmacologic Approaches to Targeting HDL

MICHAEL H. DAVIDSON, MD

Evidence to Support Aggressive Management of HDL-C: Implications of Recent Trials

ALLEN J. TAYLOR, MD

HDL as a Therapeutic Target

DANIEL J. RADER, MD

Epidemiology of CHD

THOMAS P. BERSOT, MD, PHD
STEVEN M. HAFFNER, MD

Physiology and Pathophysiology of HDL Metabolism

DANIEL J. RADER, MD

Effects of Lifestyle and Dietary Modification on HDL-C Levels

MARGO A. DENKE, MD.

Gracias  por la oportunidad